LABMT @LABMT2

Latin American Bone Marrow Transplantation Group - Helping HSCT growth in the Region - Sharing information - Strengthening ties! Joined February 2020

Tweets

571
Followers

1K
Following

780
Likes

714

LABMT @LABMT2

a month ago

Do not miss our upcoming webinar on the #EBMT26 highlights later today! 4:00 PM Mexico city time. Register here: us06web.zoom.us/meeting/regist… @TheEBMT #BMTsm

0 1 1 95 0

View Details

LABMT @LABMT2

3 months ago

Join @LABMT2 activities at #EBMT26 on March 23! See you 🔜 @TheEBMT #BMTsm #CARTcells

0 3 9 324 0

View Details

LABMT @LABMT2

5 months ago

Don't forget to meet us tonight at 8:00 PM! @LABMT2 #Tandem26 @ASTCT

LABMT @LABMT2

5 months ago

Let's meet at #Tandem26 come and join us! @ASTCT #BMTsm #CARTcells

0 5 13 1K 1

0 0 1 137 0

View Details

🇲🇽 Gomez-De-Leon 469 📘 Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: The Mexican Experience A national multicenter snapshot of outcomes, challenges, and collaboration in ALL transplantation. #Tandem26 #BMTsm

0 1 2 75 0

View Details

LABMT @LABMT2

5 months ago

🇧🇷 Brazil Schmidt-Filho 784 🦠 Real-World Effectiveness of Letermovir Prophylaxis after Allogeneic HCT in a Middle-Income Country Real-world data show reduced CMV reactivation and no resistant infections with letermovir prophylaxis. #Tandem26 #BMTsm

0 0 1 48 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Ugarte-Pelaez 🏥 Outpatient Allogeneic Hematopoietic Stem Cell Transplantation: Feasibility, Hospitalization Predictors, and Early Mortality Over 40% fully outpatient HSCT—feasible, safe, and cost-saving. #Tandem26 #BMTsm

0 2 5 127 0

View Details

LABMT @LABMT2

5 months ago

🇧🇷 Gibran-Nunes 528 💊 Loncastuximab Tesirine in Heavily Pretreated DLBCL, Including the Post–CAR-T Setting: A Meta-Analysis Systematic review shows meaningful activity with manageable toxicity in advanced DLBCL. #Tandem26 #BMTsm

0 0 0 70 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Frausto 405 🌎 Breaking Geographic Barriers in a Mexican Ambulatory Transplant Program Early outcomes show equitable access and comparable survival for national and international patients. #Tandem26 #BMTsm

0 1 2 60 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 González-Lozano 175 🚀 Safety and Feasibility of Outpatient Myeloablative TMLI-Based Allogeneic Transplantation in High-Risk ALL Phase I/II trial supporting outpatient delivery with encouraging survival and safety. #Tandem26 #BMTsm

0 1 3 314 1

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Morcos-Sandino 252 👁️ Topical Cyclosporine vs Tacrolimus for Ocular GVHD Prophylaxis after Allogeneic HSCT Phase I–II trial supporting safe and feasible ocular GVHD prevention strategies. #Tandem26 #BMTsm

0 0 1 71 0

View Details

LABMT @LABMT2

5 months ago

🇧🇷 Arcuri 246 🧪 Joint Use of Rabbit ATG and Posttransplant Cyclophosphamide for HLA-Matched PBSC Transplantation: The Jurassic Phase I/II Trial Early results support a calcineurin inhibitor–free GVHD prophylaxis strategy. #Tandem26 #BMTsm

0 0 1 85 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Sotomayor 378 🛡️ Post-Transplant Cyclophosphamide for GVHD Prophylaxis in HLA-Matched Related Donor HSCT Real-world outcomes from a Latin American center supporting PTCy in MRD transplants. #Tandem26 #BMTsm

0 0 1 61 0

View Details

LABMT @LABMT2

5 months ago

🇧🇷 | Barroso Duarte 406 ⚖️ Comparative Outcomes of Allogeneic HCT in MDS/MPN versus Other Myelodysplastic Syndromes Registry data confirm inferior survival in MDS/MPN, underscoring the need for tailored strategies. #Tandem26 #BMTsm

0 0 2 75 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Burgos-Canales 475 📊 Non-Relapse Mortality in Acute Leukemia: Haploidentical vs Matched Related Donor Unicentric Mexican experience showing comparable NRM across donor platforms. #Tandem26 #BMTsm

0 0 1 70 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Montemayor-Mora 474 🔄 Comparative Outcomes between Haploidentical and HLA-Identical Related HSCT in Northeastern Mexico Real-world evidence supporting haploidentical transplant as an effective alternative in LMICs. #Tandem26 #BMTsm

0 0 3 68 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Ugarte-Pelaez 489 🔗 Short-Duration Blinatumomab for Residual Disease Eradication as a Bridge to Transplant in B-ALL Innovative, resource-adapted strategy showing high MRD clearance before HCT. #Tandem26 #BMTsm

0 1 2 66 0

View Details

LABMT @LABMT2

5 months ago

🇧🇷 | Simioni 496 📈 Improving Hematopoietic Cell Transplantation Follow-up Data: Completeness Index Assessment of Brazilian Registry Centers How systematic monitoring and feedback improved national transplant registry data quality. #Tandem26 #BMTsm

0 0 1 64 0

View Details

LABMT @LABMT2

5 months ago

🇲🇽 Armillas-Canseco 🏥 Early Hospital Readmission after Allogeneic Hematopoietic Cell Transplantation Haploidentical donors and bacterial infections identified as key drivers of early readmission risk. #Tandem26 #BMTsm

0 0 1 95 0

View Details

LABMT @LABMT2

5 months ago

International | Fingrut 🌍 Inclusive Practices for Safe and Equitable Donor Assessment Global consensus recommendations to advance donor safety, equity, and inclusion across registries and centers. #Tandem26 #BMTsm